An evaluation of monitoring possibilities of argatroban using rotational thromboelastometry and aPTT

Schött, Ulf; Rundgren, Malin; Engström, M

Published in:
Journal of Thrombosis and Haemostasis

DOI:
10.1111/j.1538-7836.2009.03473_2.x

2009

Citation for published version (APA):

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal

Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Conclusion
A significant and strong correlation between argatroban concentrations and several ROTATIONAL THROMBOELASTOMETRY (ROTEM®) parameters were found, especially so in the clinically relevant therapeutic range up to 100 s aPTT for patients with heparin induced thrombocytopenia (HIT). Rotational thrombelastometry/thrombelastography has a potential role to increase the safety of argatroban anticoagulation in critically ill patients, like patients with heparin induced thrombocytopenia (HIT).

Introduction: The aim of the study was to study in vitro argatroban anticoagulation with ROTEM® and activated partial thromboplastin time (aPTT).

Method: Argatroban was added in vitro to a series of citrated whole blood samples from 10 healthy volunteers to obtain whole blood concentrations of 0, 0.125, 0.25, 0.5, 1.0, 2.0, 4.0 and 8.0 mg/l. Whole blood aPTT was analysed with a Free Oscillation Rheometer (FOR or ReoRox®, Medirox Sweden) and thromboelastometry ROTEM® (Pentapharm GmbH, Munich Germany).

Results: There was a significant and strong correlation between argatroban concentrations and Clotting Time (CT in ROTEM® analysis with INTEM) (p<0.0001 and r=0.98). When we studied the correlation between aPTT and CT, we found a highly significant and strong correlation between these two analyses (p<0.0001 and r=0.97). See figs1-3.

References: